Cincinnati · Montgomery · Edgewood, KY By appointment · Most insurance accepted
Contact
Request a Consultation

RegenLife Centers · Physician-led care

Degenerative Disc Disease Cincinnati OH

Non-Surgical Treatment Options

Published on October 26th, 2026

Caitlyn Benton
Written by
Caitlyn Benton
Dr. Zeeshan Tayeb
Reviewed and Approved by
Dr. Zeeshan Tayeb

The patient who has been told their imaging shows "just normal aging" has often spent years living with back pain that interrupts sleep, makes an eight-hour workday feel like a physical ordeal, and resists every treatment directed at the muscles and joints above a disc that nobody has addressed directly. The patient whose MRI report says "multi-level degenerative disc disease", and who has been handed a physical therapy referral and a prescription for anti-inflammatories as a complete response to that finding, has often not been told that the disc degeneration driving their pain is a biologically addressable problem, not an irreversible fate they must manage around for the rest of their lives.

Degenerative disc disease treatment in Cincinnati, OH at RegenLife Centers for Integrative Pain & Weight Management begins from a different clinical premise: that the more than 40% of Americans over 40 who show evidence of disc degeneration, rising to more than 80% by age 80, deserve a treatment approach commensurate with the biology of what has actually gone wrong, not a referral pathway that identifies the structural problem and then addresses only the symptomatic surface of it. Degenerative disc disease (DDD) is the most common structural contributor to chronic low back pain and neck pain in the United States, and among the most consistently undertreated with the full range of regenerative, interventional, and rehabilitative options that current evidence supports.

Female patient sitting on an examination couch indicating a back pain location to a clinician in a clinical settingFemale patient sitting on an examination couch indicating a back pain location to a clinician in a clinical setting

Key Takeaways

  • More than one-third of adults aged 40–59 have moderate to severe degenerative disc disease on imaging, with prevalence climbing above 80% in those over 80: making DDD the single most common structural driver of chronic back pain in the American adult population
  • Intradiscal PRP injection achieved a 71% success rate at 48-week follow-up, with nearly 75% of patients classified as successes at 5–9 years: establishing regenerative biological treatment as a clinically meaningful alternative to surgery for appropriately selected disc degeneration patients
  • Prolotherapy for spinal instability and discogenic low back pain produced positive outcomes in 76% of patients at 3-month follow-up, addressing the ligamentous and capsular instability that disc degeneration creates and that no amount of muscle strengthening alone can structurally correct
  • Surgery for DDD: spinal fusion, is rarely necessary, reserved for a precise set of indications involving neurological compromise, structural instability, and failure of comprehensive non-surgical care after a minimum of 6 months; the majority of DDD patients who have not received regenerative treatment have not received comprehensive non-surgical care

Understanding Degenerative Disc Disease: Anatomy, Cascade, and Why the Diagnosis Is Often Undertreated

What Happens to the Disc

The intervertebral discs are the fibrocartilaginous cushions between each vertebra of the spine, from the cervical levels of the neck through the thoracic and lumbar spine, that perform several structural functions simultaneously. The nucleus pulposus at the center of each disc is a hydrated gel-like core that absorbs compressive load and distributes it evenly across the vertebral endplates, while the surrounding annulus fibrosus, a multilayered ring of collagen fibers, contains that nucleus and resists the tensile and rotational forces that spinal movement generates. In a healthy disc, the nucleus pulposus is approximately 80–90% water; in a degenerated disc, this hydration is progressively lost, reducing the disc's height, its capacity to absorb compressive load, and its ability to distribute force evenly across the adjacent vertebral endplates.

The mechanism of degeneration involves both structural and biological loss: the nucleus loses proteoglycans, the molecules that bind and retain water, while the annular collagen fibers develop fissures and tears that allow nucleus material to herniate into or through the annular wall. The disc is the largest avascular structure in the human body, receiving its nutrition through diffusion from adjacent vertebral endplates rather than direct blood supply, which means its capacity for spontaneous repair is extremely limited, and the biological signals that would initiate fibrocartilage repair cannot reach the central disc tissue through normal circulation. This is the biological rationale for regenerative injection into the disc or peri-discal structures: delivering concentrated repair signals to tissue whose intrinsic healing capacity is structurally constrained.

The Degenerative Cascade: From Disc Loss to Nerve Compression

Disc degeneration does not affect the intervertebral disc alone. As disc height is lost, the three-joint complex at each spinal level, the disc anteriorly, and the two facet joints posteriorly, undergoes a mechanical redistribution of load that affects the entire motion segment. When a degenerated disc loses height, the apophyseal (facet) joints bear increased compressive load, accelerating their own osteoarthritic degeneration, producing facet joint hypertrophy, osteophyte formation, and thickening of the ligamentum flavum that collectively narrow the spinal canal and foramina through which nerve roots pass. The result is spinal stenosis and foraminal stenosis: the bony and soft-tissue narrowing that generates radicular pain, numbness, and weakness in the arms or legs depending on the spinal level affected.

This is the degenerative cascade that makes early identification and treatment of disc pathology clinically important: the disc pathology that begins with hydration loss and annular fissuring cascades into facet arthrosis, ligamentous hypertrophy, endplate changes, and ultimately nerve root compression, a progressive structural deterioration that is far more difficult to address regeneratively at its later stages than at its onset. A population-based cohort study found a significant association between severe lumbar disc degeneration and end-stage hip or knee osteoarthritis requiring joint replacement, reflecting the downstream biomechanical consequences of altered spinal mechanics that DDD imposes on the entire kinetic chain.

Who Gets DDD and Why It Is Frequently Undertreated

By age 20, 37% of people already show evidence of disc degeneration on imaging. By age 35, approximately 30% have measurable disc pathology; by age 60, more than 90% have some form of disc deterioration detectable on MRI. The prevalence of symptomatic DDD, moderate to severe degeneration associated with pain and functional limitation, affects one-third of adults aged 40–59, with progression occurring 40–70% more frequently in women than men. The populations most affected are those whose occupations involve prolonged spinal loading, sedentary desk work, heavy lifting, and sustained vibration exposure each accelerate disc hydration loss and annular fissuring beyond the baseline rate of age-related change.

Despite this prevalence, DDD is among the most consistently undertreated conditions in musculoskeletal medicine, for a specific reason: imaging-confirmed disc degeneration is so common in the asymptomatic population that clinicians frequently dismiss it as an incidental finding rather than a structural contributor to pain, or address only the pain without addressing the disc pathology that generates it. The result is a treatment pattern that cycles between anti-inflammatory medications, physical therapy referrals, and periodic steroid injections without ever delivering the biological intervention that the disc tissue's healing deficit requires.


Degenerative Disc Disease Cincinnati OH: Where Standard Care Falls Short

A physiotherapist performs a back alignment therapy on a patient lying down in a clinical rehabilitation settingA physiotherapist performs a back alignment therapy on a patient lying down in a clinical rehabilitation setting

The Conservative Management Plateau

The standard management pathway for lumbar and cervical disc degeneration, rest, NSAIDs, and physical therapy, is appropriate as initial care and inadequate as a final destination for patients with established discogenic pain and structural disc pathology. Physical therapy addresses the muscular deconditioning, neuromuscular compensation, and movement dysfunction that disc pain reliably produces, and a European Spine Journal systematic review confirmed that exercise therapy produces outcomes equivalent to surgical fusion for chronic low back pain associated with disc degeneration, with far fewer risks. But physical therapy does not address the disc itself: the lost nucleus hydration, the annular fissures, the endplate pathology, or the inflammatory cytokine environment within the degenerated disc that drives discogenic pain independently of the loading patterns that physical therapy modifies.

NSAIDs present the same pharmacological tension in DDD that they present in every fibrocartilaginous injury: the prostaglandin suppression that reduces pain simultaneously impairs the early inflammatory response that represents the body's own attempt to initiate repair at the disc periphery. For a structure with already severely limited intrinsic healing capacity, pharmacological suppression of the repair response is a significant biological cost in exchange for temporary symptom relief, and it is the cost that makes the standard DDD management pathway a symptom management strategy rather than a structural treatment.

Epidural Steroid Injections: Short-Term Relief, Unaddressed Biology

Epidural steroid injections represent the most common interventional procedure applied to DDD-related pain, and a clinically appropriate tool for managing the radicular inflammation that nerve root compression from disc herniation or spinal stenosis produces. In the cervical spine, 54–80% of patients report significant improvement in pain and functional outcomes at 6 months to 2 years with a series of 3–6 injections, and lumbar epidural steroids produce meaningful short-term pain relief for the radicular component of lumbar disc disease. But epidural steroids address the inflammatory consequences of disc pathology, the nerve root inflammation produced by disc material contact and mechanical compression, not the disc degeneration itself. The steroid that reduces the nerve root's inflammatory response does nothing for the degenerated nucleus, the fissured annulus, or the vertebral endplate pathology that will continue generating discogenic pain and the radiculitis that follows when the steroid effect wears off.

For patients with predominantly axial discogenic low back pain, pain centered in the spine rather than radiating down the limb, no strong evidence currently supports lumbar epidural steroids as a primary management strategy, because the pain generator is the disc itself rather than the nerve root the steroid reaches. Regenerative treatment directed at the disc is the biologically correct intervention for discogenic pain, not an epidural that targets the structure adjacent to the problem.


PRP Therapy for Degenerative Disc Disease: The Biological Case

A healthcare professional administering an injection to a patient in a clinical setting, representing regenerative treatment for disc pathologyA healthcare professional administering an injection to a patient in a clinical setting, representing regenerative treatment for disc pathology

How PRP Addresses the Disc Degeneration Problem

PRP therapy concentrates the patient's own platelets, and the growth factors they carry, to 3–8 times their baseline blood levels, then delivers that biological payload to the degenerated disc or peri-discal structures under fluoroscopic or ultrasound guidance. The growth factors in PRP, platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), and insulin-like growth factor-1 (IGF-1), are precisely the signaling molecules that nucleus pulposus cells and annular fibrochondrocytes require to initiate proteoglycan synthesis, collagen repair, and extracellular matrix restoration. By delivering these signals directly to a structure that cannot receive them through normal blood-borne circulation, PRP creates the biological repair environment that disc tissue cannot generate on its own.

Within the disc environment, PRP also produces a clinically important anti-inflammatory effect: the degenerated disc is characterized by elevated levels of pro-inflammatory cytokines, TNF-α, IL-1β, IL-6, that amplify discogenic pain and accelerate matrix breakdown beyond the rate of mechanical wear alone. PRP's growth factor payload modulates this cytokine environment, shifting the disc from a catabolic inflammatory state toward the anabolic repair state required for structural restoration. Higher-concentration PRP preparations appear to produce better outcomes: satisfaction rates of 81% were reported in patients receiving higher-concentration PRP (>10×) compared to 55% in those receiving lower-concentration preparations (<5×), establishing PRP concentration as a clinically important variable in disc degeneration treatment.

What the Clinical Evidence Shows

The research base for intradiscal and peri-discal PRP in degenerative disc disease has grown substantially and consistently supports the approach as a meaningful non-surgical treatment. A prospective clinical trial found that intradiscal PRP injection achieved a 71% success rate at 48-week follow-up, with pain VAS scores significantly improving from 69.7 mm to 43.3 mm, a clinically meaningful reduction achieved in tissue that has no spontaneous healing capacity without biological supplementation. Longer-term data are particularly compelling: nearly 75% of patients were classified as successes at 5–9-year follow-up, with 91% experiencing significant improvements in pain and disability scores, outcomes that demonstrate biological repair that consolidates and persists over time rather than temporary symptomatic relief.

A recent scoping review of 14 clinical studies evaluating PRP for stage III and IV degenerative disc disease, the moderate-to-severe presentations that most patients receiving this diagnosis carry, found all studies reporting significant improvement in clinical and functional scores, with PRP characterized as clinically effective, low-cost, and carrying a uniformly favorable safety profile with no serious adverse events. Modified Macnab criteria excellent and good rates reached 93.3% in one high-quality series. These are not experimental outcomes; they are consistent findings across multiple study designs in a population for whom standard care produces a familiar ceiling of partial improvement.

Who Responds Best to PRP for Disc Degeneration

The patients most likely to achieve durable benefit from PRP for DDD are those with Pfirrmann grade II–IV disc degeneration (mild to moderate, not end-stage collapse), those with predominantly discogenic pain rather than primarily facet-mediated pain, patients with one or two symptomatic levels rather than diffuse multilevel degeneration, and those who have completed physical therapy with incomplete improvement. Patients who demonstrate meaningful pain reduction with diagnostic peri-discal injection confirming disc-origin pain are particularly strong PRP candidates, because the positive diagnostic response confirms the disc as the pain generator and the intra-discal environment as accessible to the biological signals PRP delivers.

The regenerative program at RegenLife delivers intradiscal and peri-discal PRP under image guidance, confirming precise anatomic placement, and sequences the injection protocol with the physical rehabilitation that allows biological repair to consolidate under mechanically appropriate conditions.


Prolotherapy for Spinal Instability and Discogenic Pain

Why DDD Involves More Than the Disc

The intervertebral disc does not support spinal stability in isolation. The posterior longitudinal ligament, the anterior longitudinal ligament, the interspinous and supraspinous ligaments, and the facet joint capsules collectively create the passive stabilizing environment in which the disc distributes compressive load. In patients with DDD, particularly those with facet arthrosis, multilevel degeneration, or a history of repetitive loading injury. These periarticular ligamentous structures develop their own insufficiency, allowing abnormal segmental motion that continuously stresses the degenerated disc beyond what the annular fibers can resist and that generates pain from the mechanosensitive structures within and around the disc independently of the disc's own degeneration.

Prolotherapy, targeted injection of concentrated dextrose to the spinal ligament insertions and facet capsules, initiates the fibroblastic repair response that restores tensile integrity to overstretched or damaged spinal ligaments, reducing the abnormal segmental motion that stresses the disc and creating the passive stability environment in which disc repair can consolidate into durable structural recovery. For patients with combined disc degeneration and spinal ligamentous laxity, a pattern that is particularly common in patients with hypermobility, prior spinal trauma, or chronic repetitive loading, PRP to the disc and prolotherapy to the facet capsules and ligament insertions address both layers of the structural deficit simultaneously.

The Clinical Evidence

A published clinical study of patients with chronic low back pain and MRI-confirmed lumbar degenerative disc disease treated with fluoroscopically guided prolotherapy found positive clinical outcomes in 76% of patients at 3-month follow-up, with improvements in pain, function, and quality of life, outcomes that reflect the mechanical stability restoration prolotherapy produces in a joint system where ligamentous insufficiency is compounding the disc pathology's pain contribution. For the broader spinal osteoarthritis and discogenic pain population, the evidence for prolotherapy as an adjunct to comprehensive regenerative management is mechanically well-grounded: by restoring passive spinal stability, prolotherapy reduces the mechanical insult that continues to stress the degenerated disc during activities that standard rehabilitation cannot adequately modify.

For patients with associated facet joint degeneration, an almost universal finding in patients with established disc degeneration, given the linked mechanics of the spinal three-joint complex, intra-articular dextrose prolotherapy to the facet joints has demonstrated significant improvements in back pain and function in published randomized controlled trial data, addressing the posterior element contribution to spinal pain that disc-directed treatment alone may not fully resolve. The clinical approach at RegenLife combines disc-targeted PRP with prolotherapy to the periarticular stabilizing structures for patients whose evaluation confirms both contributions, because treating the disc without treating the mechanical environment in which it must function is the same incomplete approach as treating the meniscus without treating the knee capsule.


Physical Rehabilitation: The Essential Partner to Regenerative Care

A therapist stretching a patient's back during a physical therapy session, supporting spinal rehabilitation for degenerative disc diseaseA therapist stretching a patient's back during a physical therapy session, supporting spinal rehabilitation for degenerative disc disease

Why Sequencing Matters

Physical therapy as the first and only treatment for symptomatic DDD produces a familiar outcome pattern: meaningful improvement during the rehabilitation program, followed by gradual recurrence when loading resumes, because the strengthened paraspinal, gluteal, and core musculature is now operating around a disc structural deficit and mechanical environment that no amount of muscle strengthening can resolve at the tissue level. The biologically appropriate sequencing is regenerative injection to address the disc-level and ligamentous structural deficit first, followed by physical therapy directed at the neuromuscular compensation patterns that chronic disc pain reliably produces and the strength deficits that unloading and protective movement avoidance entrench.

A European Spine Journal systematic review confirmed that exercise therapy produces long-term outcomes equivalent to surgical fusion for chronic discogenic low back pain, not because exercise resolves disc degeneration, but because the neuromuscular restoration it produces around a disc environment that regenerative treatment has improved achieves the same functional recovery as fusion without the structural costs and recovery burden of surgery. The evidence supports an integrated approach in which regenerative treatment and physical rehabilitation are sequenced together, not chosen between.

Components of Effective Spinal Rehabilitation for DDD

Physical therapy at RegenLife for degenerative disc disease targets four functional domains that disc pathology consistently disrupts. Deep spinal stabilizer activation, the multifidus and lumbar transversus abdominis co-contraction that provides segmental control at the motion segments most affected by disc degeneration, is restored through progressive motor control training that begins with low-load activation exercises before progressing to loaded movement patterns. Posterior chain strength and hip extension loading, gluteal and hamstring activation patterns that reduce lumbar compressive loading and protect the posterior disc during dynamic activity, is the second priority. Thoracic mobility restoration addresses the thoracic stiffness that lumbar and cervical disc pathology both produce and compound, redistributing movement demand away from the most degenerated segments. Functional movement pattern retraining, correcting the altered bending mechanics, reduced hip hinge patterns, and compensatory lumbar loading strategies that chronic disc pain entrains, is the final phase before return to full loading.

Exercise therapy complements the physical therapy program with the progressive cardiovascular and resistance training that maintains disc nutrition through the cyclic loading that drives fluid exchange across the avascular endplates, disc nutrition is movement-dependent, and the sedentary patterns that disc pain often produces are themselves a biological contributor to accelerated degeneration.

Chiropractic Care and Spinal Segmental Motion

Degenerative disc disease creates predictable patterns of segmental hypomobility at the degenerated levels and compensatory hypermobility above and below, a mechanical pattern that sustains both pain and the abnormal loading asymmetry that accelerates adjacent-level degeneration. Chiropractic care targeting the spinal motion segments restores the segmental mobility that degeneration and protective muscle guarding restrict, reducing the mechanical stress concentration at symptomatic levels and allowing the rehabilitation program to develop strength and motor control in a mechanically appropriate spinal environment. For patients with multilevel disc degeneration and associated thoracic or cervical restriction, chiropractic evaluation and treatment as part of the integrated care plan addresses the kinematic chain above the primary pathology rather than treating the affected level in isolation.


When Surgery Is the Right Answer for Degenerative Disc Disease

The Precise Indications for Surgical Referral

Regenerative treatment is the appropriate first structural intervention for most DDD presentations, but there are specific clinical scenarios in which surgical evaluation is the correct next step and regenerative treatment is not an adequate substitute. Cauda equina syndrome, bilateral leg weakness or numbness, bowel or bladder dysfunction from severe lumbar spinal stenosis, is a neurological emergency requiring urgent surgical decompression. Progressive neurological deficit, worsening motor weakness in the arms or legs that continues to deteriorate despite conservative management, indicates nerve compression that surgical decompression must relieve before the deficit becomes permanent.

Outside of these acute neurological emergencies, the surgical indications are more selective than the standard referral pathway reflects. Patients with severe structural instability, demonstrable spondylolisthesis with neurological compromise, significant vertebral collapse, may require surgical stabilization that regenerative treatment cannot adequately address. True failure of comprehensive nonsurgical management after a minimum of 6 months, including regenerative treatment, more than physical therapy and anti-inflammatories, is the appropriate threshold for surgical consideration in non-emergent DDD. The patient who has received only medications, steroid injections, and physical therapy has not been comprehensively treated non-surgically; they have received symptom management, and the distinction is clinically significant.

Choosing the Right Procedure When Surgery Is Indicated

For patients whose disc pathology ultimately requires surgical management, the evidence distinguishes meaningfully between decompression alone, when structurally appropriate, and fusion. Spinal fusion eliminates motion at the treated level entirely, sacrificing the flexibility and load-sharing that the mobile segment provided, and creating adjacent-segment stress that accelerates degeneration at the levels above and below the fusion over time. Decompression without fusion, when biomechanically appropriate for the specific pathology, preserves motion while addressing the neural compression, and represents a structurally less costly intervention for appropriately selected candidates. The role of PRP as intraoperative augmentation of bone graft healing in fusion procedures is an active area of research, with regenerative treatment extending into the surgical setting for patients whose pathology reaches that threshold.


The Integrated Evaluation at RegenLife: Degenerative Disc Disease Cincinnati OH

A doctor examining a spine X-ray film, reviewing diagnostic imaging for degenerative disc disease assessment and treatment planningA doctor examining a spine X-ray film, reviewing diagnostic imaging for degenerative disc disease assessment and treatment planning

Effective non-surgical treatment of degenerative disc disease in Cincinnati, OH begins with an evaluation designed to characterize the disc pathology precisely, identifying the specific levels involved, the Pfirrmann grade and structural status of each disc, the degree of associated facet joint and ligamentous involvement, the presence and extent of neural compression, and the biomechanical pattern of spinal loading that is driving progression, not simply confirming that disc degeneration is present. The diagnostic services at RegenLife assess MRI findings in relation to the clinical presentation, identifying the discordance between imaging findings and symptoms that makes anatomic diagnosis by imaging alone unreliable, and confirming the pain generator through clinical and, when indicated, diagnostic interventional evaluation.

The evaluation also includes assessment of the systemic factors that impair regenerative outcomes independently of how precisely the injection is placed. Insulin resistance reduces growth factor receptor signaling in disc cells, diminishing the biological response to PRP regardless of concentration. Systemic inflammation, elevated CRP, elevated inflammatory cytokines, drives the catabolic environment within the degenerated disc toward accelerated matrix breakdown rather than repair. Hormonal deficiencies, testosterone and growth hormone in male patients, estrogen in postmenopausal women, reduce the anabolic capacity on which disc tissue repair depends. The hormone therapy and lifestyle medicine components of the RegenLife protocol address these systemic contributors directly, because the patient with uncontrolled metabolic disease and significant hormonal deficiency is a fundamentally different biological environment than one with optimized metabolic health, and the difference in regenerative outcome reflects this.

The interventional procedures, image-guided intradiscal or peri-discal PRP for disc pathology, prolotherapy for spinal ligamentous and facet capsule instability, and the progressive physical rehabilitation that consolidates repair under mechanically appropriate loading, are selected and sequenced based on diagnostic findings rather than applied uniformly. The goal is not a single injection: it is a recovered spine that avoids both surgery and the progressive degeneration that untreated disc pathology accelerates.


Contact RegenLife Centers to schedule an evaluation or ask which service fits your needs.


Frequently Asked Questions

Find answers to common questions

Ready to Learn More?

To learn more and to find out if you might be a good candidate at RegenLife, schedule a consultation with our team today.

About the Author

Caitlyn Benton

Caitlyn Benton, Research Manager at RegenLife

As Research Manager, Caitlyn Benton oversees the strategic planning and execution of clinical research projects, ensuring all studies adhere to the highest regulatory and ethical standards. With expertise in protocol development and data monitoring, she coordinates multidisciplinary teams to ensure the integrity of our clinical research programs and the accuracy of the insights shared with our patients.

Reviewed and Approved by

Dr. Zeeshan Tayeb

Dr. Zeeshan Tayeb, Medical Director at RegenLife

Interventional Spine, Pain, and Sports Medicine Dr. Zeeshan Tayeb, MD is board-certified in Pain Medicine and Physical Medicine & Rehabilitation, with specialized fellowship training in interventional spine, pain, and sports medicine. He sees patients at Pain Specialists of Cincinnati/RegenLife in Cincinnati, Ohio. Dr. Tayeb's background in physical medicine and rehabilitation has provided the foundation for his comprehensive approach to treating the whole person. Dr. Tayeb has done extensive training and education in both functional and regenerative medicine and specializes in state-of-the-art treatments, including laser therapies, PRP and stem-cell injections, and nutritional and hormonal optimization.

Disclaimer:

As a service to our readers, RegenLife provides access to our library of archived content. Please note the date of last review or update on all articles.

No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

Stay Updated With Our Latest News

Check back regularly for new articles and updates about pain management treatments, practice news, and health tips from our team of specialists.

Get In Touch

Same-week consults. Real follow-through.

Tell us what's going on. A coordinator will follow up during office hours to help book your visit.

Request a consultation

Choose the clinic that works for you.

Most new patients can be seen within the same week.

Cincinnati

3328 Westbourne Dr

Cincinnati, OH 45248

(513) 922-2204

Edgewood

162 Barnwood Dr

Edgewood, KY 41017

(859) 331-4159

Montgomery

9989 Montgomery Rd

Montgomery, OH 45242

(513) 922-2204

We accept most major insurance plans

RequestCallDirections